RESTORE is a pragmatic cluster-randomised trial in 26 polyclinics across Harare, Bulawayo and Mashonaland East, Zimbabwe, testing whether integrating mental health, diabetes, nutritional, pulmonary and peer-led support into routine TB care can address the multiple long-term conditions that often accompany TB. Led by the London School of Hygiene and Tropical Medicine with the University of Sydney and investigators from LMU Klinikum, in partnership with Zimbabwe's Ministry of Health and Child Care, the National TB Programme, and the Harare and Bulawayo city health departments, it is funded by UKRI and NHMRC through the Global Alliance for Chronic Disease. Starting in January 2026, the study uses the six-month TB treatment period to move beyond siloed services and improve long-term health and socio-economic outcomes for TB survivors.

This single-centre observational study uses advanced cardiac imaging and biochemical profiling to characterise heart disease in 350 adults with confirmed pulmonary TB and 150 matched comparators without TB.

Led by LSHTM and LMU Munich with funding from the Novo Nordisk Foundation, it began in April 2026.

Findings will guide interventions to improve TB treatment outcomes and reduce post-TB disability.